Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Psychopharmacology (Berl). 2012 Jun 4;224(2):289–301. doi: 10.1007/s00213-012-2752-7

Fig. 4.

Fig. 4

Data reflect extracellular dopamine levels in the NAcc expressed as a percentage of basal values (± SEM) in control and nicotine-treated rats that were pre-treated with U50,488 as in the behavioral studies. Separate groups of adult control (n=7) and nicotine-treated (n=7) rats were included. U50,488 (5 mg/kg) significantly decreased dopamine overflow in control and nicotine-treated rats relative to baseline (*p ≤ 0.05). The decreases in dopamine were larger in nicotine-treated adults as compared to controls (†p ≤ 0.05). The figure insets reflect the mean total AUC (± SEM) following U50,488. These data show that nicotine-treated adults displayed decreases in NAcc dopamine following U50,488 that were lower relative to adult controls (†p ≤ 0.05).